Catalog No.: PC-26304Not For Human Use, Lab Use Only.
Enlicitide (MK-0616) is a highly potent, orally bioavailable macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with Ki of 5 pM, binds to the LDLR binding domain of PCSK9.
Enlicitide (MK-0616) is a highly potent, orally bioavailable macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with Ki of 5 pM, binds to the LDLR binding domain of PCSK9. Enlicitide (MK-0616) inhibitsPCSK9 with an IC50 2.5 nM in human plasma. Enlicitide (MK-0616) has no observed off-target activity at 10 µM in 122 receptor, ion channel, enzyme radioligand binding, and cellular assays in the Eurofins Cerep Panlabs screening panel. Enlicitide (MK-0616) is not only able to reduce LDL-cholesterol, non-HDL-cholesterol, and apoB, but can also lower Lp(a).
